A breakthrough clinical study has confirmed the efficacy of Frutarom BU Health’s Neurovena green oat extract on acute improvement in cognitive performance.
The placebo-controlled, double-blind, randomised cross-over study investigated the effects of 800mg of Neuravena on cognitive performance, using the Computerized Mental Performance Assessment System (Compass) – a battery of tests selected to allow assessments across the major cognitive domains, including global functioning such as speed and accuracy, attention, working and episodic memory and executive function.
The study shows that a single 800mg dose of Neuravena provided significant benefits related to cognitive function. The results of the study indicated a significant improvement in the “speed of performance” measure across all the timed tasks within the cognitive tests battery, indicating general benefit to brain function, Frutarom claimed.
“The maintenance of cognitive function even in stressful situations has become essential in our society, based on performance and changing social trends. The need to think better or stay more concentrated and focused, be it at work, during an exam or at home… is becoming increasingly important,” the Israeli-headquartered company added.
Nicolas Meyrial, vice president of sales and business development for Frutarom BU Health North America, said: “We are committed to science and technology, and focus on proprietary studies that support the efficacy and safety of our ingredients. This new clinical study – the fifth on Neuravena – confirms that ongoing commitment.”
Frutarom will showcase Neurovena, an extract of a proprietary variety of green oat, at SupplySide West in Las Vegas later this month.
© FoodBev Media Ltd 2024